Cheung v. Bristol-Myers Squibb Co.

282 F. Supp. 3d 638
CourtDistrict Court, S.D. Illinois
DecidedOctober 12, 2017
Docket17cv6223(DLC); 17cv6239(DLC); 17cv6243(DLC); 17cv6245(DLC)
StatusPublished
Cited by6 cases

This text of 282 F. Supp. 3d 638 (Cheung v. Bristol-Myers Squibb Co.) is published on Counsel Stack Legal Research, covering District Court, S.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cheung v. Bristol-Myers Squibb Co., 282 F. Supp. 3d 638 (S.D. Ill. 2017).

Opinion

DENISE COTE, District Judge:

This Opinion is issued in connection with products liability MDL litigation concerning the brand name pharmaceutical Eliquis, a blood thinner used to treat nonvalvular atrial fibrillation and to reduce the risk of stroke and systemic embolism. At *640issue here are four related Eliquis lawsuits filed by the law firm Salim-Beasley in Delaware state court, which were removed by the defendants to federal court and recently transferred to this district pursuant to the MDL process. The plaintiffs have moved to remand their lawsuits to Delaware state court. Before addressing the motion for remand, some procedural history is in order.

BACKGROUND

The first decision in the Eliquis MDL on a motion to dismiss was issued in Utts v. Bristol-Myers Squibb Co. et al., 16cv5668 (DLC) (" Utts"). On March 21, 2017, as that motion to dismiss was being addressed, a scheduling Order provided that "any action presently assigned to this Court ... may file an amended complaint fourteen (14) days after the Court decides the motion to dismiss" in Utts. The March 21 Order further provided that "any action transferred or reassigned to this Court after the Utts motion to dismiss has been decided shall have fourteen (14) days following arrival on this Court's docket to file an amended complaint."

On May 8, this Court issued its opinion in Utts.See Utts v. Bristol-Myers Squibb Co. et al., 251 F.Supp.3d 645 (S.D.N.Y. 2017). The decision dismissed the action, primarily on the ground of preemption. In accordance with the March 21 Order, a scheduling Order on May 9 ("May 9 Order") provided that "any future action transferred or reassigned to this Court shall have fourteen days following arrival on this Court's docket to file an amended complaint and show cause in a memorandum no longer than 20 pages why the amended complaint should not be dismissed based on the analysis in the May 8 Utts Opinion."

In response to the decision dismissing the Utts action, Salim-Beasley voluntarily dismissed thirty-three product liability actions concerning Eliquis brought on behalf of various plaintiffs that were pending in federal court and refiled them in Delaware state court.1 The defendants removed them to Delaware federal court, and on June 27, the Honorable Leonard P. Stark of the United States District Court for the District of Delaware denied motions to remand the thirty-three cases. Young v. Bristol-Myers Squibb Co., 2017 WL 2774735 (D. Del. June 27, 2017). Judge Stark held that the removal to federal court was properly based on diversity jurisdiction despite the defendants' citizenship in Delaware. Id. at *3.

Salim-Beasley has filed additional actions concerning Eliquis for other plaintiffs in Delaware state court, including the four at issue here. One of the four actions was filed in Delaware state court on July 5, 2017; the other three were filed on July 7, 2017. They were removed by the defendants to federal court no later than four days after they were filed and before the plaintiffs could serve the defendants.2 As Judge Stark noted, under the Rules of Civil Procedure for the Superior Court of the State of Delaware, a plaintiff cannot immediately serve a defendant after commencing an action. See Young, 2017 WL 2774735, at *1 ; Del. Sup. Ct. R. Civ. P. 4 (requiring plaintiffs to coordinate with the sheriff of the county for service).

*641After the four actions were removed, they were "tagged" for transfer to the MDL on or before July 13.3 The Judicial Panel on Multidistrict Litigation ("JPML") transferred the four actions to this Court on July 31, in the case of the first-filed action, and on August 7, in the case of the remaining three actions. Understanding that a motion for remand may expire within 30 days of removal, see 28 U.S.C. § 1447(c), Salim-Beasley filed motions for remand in each of the four actions after the actions were transferred to the MDL.4 The motions were filed on August 3 and 9.5

On August 11, Salim-Beasley notified this Court that it had filed the remand motions before the actions had officially arrived on this Court's docket because of the deadline that governs a remand motion. It asked for an extension of the deadlines set forth in the Court's May 9 Order, as well as a conference for scheduling purposes. An August 17 Order acknowledged Judge Stark's June 27 decision denying the remand motions in the thirty-three related cases, denied the request for an extension of the deadlines set forth in the May 9 Order, and required any plaintiff seeking remand to "also address in its show cause memorandum why the motion for remand should not be denied for reasons given in Judge Stark's June 27 Opinion."

Although permitted to file amended complaints in response to the guidance given in Utts, none of the plaintiffs in these four actions opted to do so. In its August 30 omnibus response to the order to show cause, Salim-Beasley addressed Judge Stark's June 27 Opinion and argued for remand. The defendants filed a response on September 13.

DISCUSSION

Federal law permits defendants to remove to federal court an action originally filed in state court if it could have been brought in federal court:

Except as otherwise expressly provided by Act of Congress, any civil action brought in a State court of which the district courts of the United States have original jurisdiction, may be removed by the defendant or the defendants, to the district court of the United States for the district and division embracing the place where such action is pending.

28 U.S.C. § 1441(a). When the sole basis for removal is § 1441(a), "all defendants who have been properly joined and served must join in or consent to the removal of the action." 28 U.S.C. § 1446(b)(2)(A). Federal courts construe the removal statute narrowly. Purdue Pharma L.P. v. Kentucky, 704 F.3d 208, 213 (2d Cir. 2013). To effect removal, a defendant must act promptly.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Torres v. O'Brien-Briggs
E.D. New York, 2020
Delaughder v. Colonial Pipeline Co.
360 F. Supp. 3d 1372 (N.D. Georgia, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
282 F. Supp. 3d 638, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cheung-v-bristol-myers-squibb-co-ilsd-2017.